Evidence map›Paper›PMID 34272933›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2021

Redox-Mediated Artificial Non-Enzymatic Antioxidant MXene Nanoplatforms for Acute Kidney Injury Alleviation.

Xing Zhao, Li-Ya Wang, Jia-Meng Li, Li-Mei Peng, Chun-Yan Tang, Xiang-Jun Zha, Kai Ke, Ming-Bo Yang, Bai-Hai Su, Wei Yang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
6.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 123 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Advances in Nano-Immunomodulatory Systems for the Treatment of Acute Kidney Injury.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Xing ZhaoCollege of Polymer Science and Engineering, Sichuan University, State Key Laboratory of Polymer Materials Engineering, Chengdu, Sichuan, 610065, China.
Li-Ya WangDepartment of Nephrology, Med-X Center for Manufacturing, West China Hospital, Sichuan University, Chengdu, 610041, China.
Jia-Meng LiDepartment of Nephrology, Med-X Center for Manufacturing, West China Hospital, Sichuan University, Chengdu, 610041, China.
Li-Mei PengCollege of Polymer Science and Engineering, Sichuan University, State Key Laboratory of Polymer Materials Engineering, Chengdu, Sichuan, 610065, China.
Chun-Yan TangCollege of Polymer Science and Engineering, Sichuan University, State Key Laboratory of Polymer Materials Engineering, Chengdu, Sichuan, 610065, China.
Xiang-Jun ZhaCollege of Polymer Science and Engineering, Sichuan University, State Key Laboratory of Polymer Materials Engineering, Chengdu, Sichuan, 610065, China.
Kai KeCollege of Polymer Science and Engineering, Sichuan University, State Key Laboratory of Polymer Materials Engineering, Chengdu, Sichuan, 610065, China.
Ming-Bo YangCollege of Polymer Science and Engineering, Sichuan University, State Key Laboratory of Polymer Materials Engineering, Chengdu, Sichuan, 610065, China.
Bai-Hai SuDepartment of Nephrology, Med-X Center for Manufacturing, West China Hospital, Sichuan University, Chengdu, 610041, China.
Wei YangCollege of Polymer Science and Engineering, Sichuan University, State Key Laboratory of Polymer Materials Engineering, Chengdu, Sichuan, 610065, China.ORCID 0000-0003-0198-1632
Sichuan University · CN

Funding

National Natural Science Foundation of China 51721091National Natural Science Foundation of China 51873126Science and Technology Achievement Transformation Fund of West China Hospital of Sichuan University CGZH19006State Key Research Program of China 2016YFC1103003State Key Research Program of China 2016YFC1103004
6 · The paper itself

Abstract

Acute kidney injury (AKI), as a common oxidative stress-related renal disease, causes high mortality in clinics annually, and many other clinical diseases, including the pandemic COVID-19, have a high potential to cause AKI, yet only rehydration, renal dialysis, and other supportive therapies are available for AKI in the clinics. Nanotechnology-mediated antioxidant therapy represents a promising therapeutic strategy for AKI treatment. However, current enzyme-mimicking nanoantioxidants show poor biocompatibility and biodegradability, as well as non-specific ROS level regulation, further potentially causing deleterious adverse effects. Herein, the authors report a novel non-enzymatic antioxidant strategy based on ultrathin Ti

Indexed as

Acute Kidney InjuryAntioxidantsApoptosisHumansKidneyOxidation-ReductionOxidative StressPolyvinylsPyrrolidinesReactive Oxygen SpeciesSignal TransductionTitaniumAntioxidantspoly(N-vinylpyrrolidine)PolyvinylsPyrrolidinesReactive Oxygen SpeciesTitaniumtitanium carbideacute kidney injuryMXenenon-enzymatic antioxidantoxidative stressredox

Identifiers

PMID34272933
PMCPMC8456282
OpenAlexW3181379018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.